Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Albendazole · 1 trial · 1 indication
AUC (0-t) was evaluated using the trapezoid rule.
AUC (0-inf) was evaluated using the trapezoid rule.
Cmax was depicted from plasma concentration of Albendazole.
| Arm | Type | Description |
|---|---|---|
| Albendazole tablet (Aqua Based) | EXPERIMENTAL | Albendazole tablets 400 milligram (mg) manufactured under aqua based solvent condition taken orally with 200 millilitre (mL) of water as single dose treatment. |
| Albendazole tablet (Alcohol Based) | ACTIVE_COMPARATOR | Albendazole tablets 400 mg manufactured under ethanol based solvent condition taken orally with 200 mL of water as single dose treatment. |
| Name | Type | Description |
|---|---|---|
| Albendazole | DRUG | Albendazole tablets 400 mg |
Inclusion Criteria: 1. Male aged from 18 years up to 40 years (inclusive). 2. Body mass index within the range of 19-24kg/m\^2. 3. Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or physical examination. 4. Negati...
Albendazole is used to treat helminthiasis, a parasitic worm infection. It is an infectious disease therapy developed by GSK plc under the ticker GSK. The drug is a small molecule and is also known as Albendazole 400 mg. Clinical development has focused on a bioequivalence study in a Chinese population.
Albendazole is developed by GSK plc, which trades under the ticker GSK. The company is the sponsor associated with the clinical trial of Albendazole 400 mg tablets. GSK plc is a global pharmaceutical company, and this asset falls within its infectious disease portfolio.
Albendazole is in Phase 1 clinical development. The only listed trial is a completed Phase 1 bioequivalence study of Albendazole 400 mg tablets. No active trials are currently recorded. The drug remains investigational and is not described as approved in the available development information.
Albendazole has been studied in one completed clinical trial, NCT01755637, titled Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population. It was a Phase 1, randomized, active-controlled trial with 56 enrolled male healthy volunteers aged 18 years and older, conducted in China.